Treatment-agnostic joint modeling of longitudinal circulating tumor dna predicts survival across first-line regimens in metastatic non-squamous NSCLC
Early ctDNA monitoring and modeling have the potential to significantly enhance treatment personalization. By enabling the early prediction of patient outcomes across various treatment regimens, this treatment-agnostic model supports more informed clinical decision-making, ultimately improving patient management and outcomes in oncology.
Authors
- Steven Xu (ORCID: https://orcid.org/0000-0001-6997-5533)
- Xin Lin (ORCID: https://orcid.org/0000-0002-8834-9850)
- Haolun Ding (ORCID: https://orcid.org/0000-0002-6771-3211)
- Shuli Qu (ORCID: https://orcid.org/0000-0002-7824-0210)
- Min Yuan (ORCID: https://orcid.org/0000-0002-7172-7253)
- Yaning Yang (ORCID: https://orcid.org/0000-0002-2671-1519)
Institutions
- University of Science and Technology of China (CN)
- Anhui Medical University (CN)
- Genmab (United States) (US)
Publication Details
- Journal
- European Journal of Pharmaceutical Sciences
- Published
- 2025-09-16
- DOI
- https://doi.org/10.1016/j.ejps.2025.107275
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00